Friday, November 18, 2016

HOPE ON THE HORIZON

Ronald S. Lauder speaking at the ADDF luncheon.  While there are currently over 3,000 ongoing clinical trials for cancer treatments, there are only 100 or so for Alzheimer’s even though 500,000 people in the US will die of the disease this year.  Following a venture philanthropy investment model, the ADDF has funded 20 of these pioneering trials. The organization’s aim is to fast track drugs to treat and cure Alzheimer’s and other causes of dementia by supporting underfunded research areas such as preclinical drug discovery and early-stage clinical trials of potential drug targets.
ALZHEIMER’S DRUG DISCOVERY FOUNDATION
SEVENTH ANNUAL FALL SYMPOSIUM & LUNCHEON
Nov. 14, 2016
by Delia von Neuschatz


“I’ve called Alzheimer’s the greatest equal-opportunity disease,” says Ronald Lauder at the Alzheimer’s Drug Discovery Foundation’s (ADDF) Seventh Annual Fall Symposium & Luncheon held at the Pierre hotel. “It strikes men and women — all races, religions, rich and poor, democrats, republicans ... even independents.”  Today, this neurodegenerative disease — the most common cause of dementia — afflicts some 44 million people worldwide including 5.5 million people in the U.S. An estimated 500,000 Americans will die from Alzheimer’s this year alone. By contrast, during the same period, 40,000 Americans will succumb to breast cancer while 40,000 will perish from prostate cancer, according to Mr. Lauder. 

Donald Newhouse, recipient of the Charles Evans Award at the ADDF Hope on the Horizon symposium and luncheon, spoke movingly of his beloved wife, Susan Newhouse (pictured), who had suffered from primary progressive aphasia, a form of frontotemporal dementia.
Alzheimer’s, in fact, is the only top 10 cause of death that cannot be prevented, cured or slowed. But, there is reason to be optimistic. Promising new treatments for dementia are currently in clinical trials and will be debuted as early as next month. 

A number of these remedies, which include both existing and new drugs, were unveiled at the ADDF symposium, appropriately named Hope on the Horizon.  Led by Howard Fillit, M.D., ADDF’s Founding Executive Director and Chief Science Officer, a panel of leading scientists in Alzheimer’s drug research delineated the multi-pronged approach to treatment which includes vascular and genetic therapies. “It is thanks to the hard work of Howard, the ADDF staff, and the scientists that we fund across the globe that we are closer than ever to having effective drugs that will fight these diseases,” says Mr. Lauder.

After the symposium, at a luncheon hosted by Paula Zahn, Bonnie Pfeifer Evans presented the Charles Evans Award to Donald Newhouse in recognition of his extraordinary commitment to dementia research and his support of the Treat FTD Fund, a joint initiative of the ADDF and the Association for Frontotemporal Degeneration. 

Attendees included:  Jo Carole Lauder, Judy Glickman Lauder, William P. Lauder and Lori Tritsch, Gary Lauder, Nancy Goodes, Mary Ann Freda, Meryl Comer, Alice Shure, George and Joan Schiele, Bonnie Engelbardt Lautenberg, Wendy Stapleton Reyes, Frances Scaife, Carol Weisman, Sharon Sager, Thia Breene, Jane Hudis, Renee  and Robert Belfer, Barbara Tober, Jan Willinger, Deborah Krulewitch, Lawrence Leeds Jr., Gregor Medinger, Paul Fribourg, Joanna and Daniel Rose, Kari Tiedemann, Mary Rudin, Maria Savettiere, Sheila Johnson Robbins, Joan Sutton Strauss and Sue Chalom. 

The program’s 300+ assembled guests succeeded in raising close to $1 million. 100% of donations to the ADDF go directly to research and drug development.
The Pierre Hotel, site of Hope on the Horizon, the ADDF’s Seventh Annual Fall Symposium and Luncheon
In excess of 300 guests were in attendance, raising close to $1 million.
Founded in 1998 by Leonard A. and Ronald S. Lauder, the Alzheimer’s Drug Discovery Foundation is the only public charity focused on accelerating the discovery of drugs to prevent, treat and cure Alzheimer’s disease.  Its venture philanthropy model supports research in academia and the biotech industry.  To date, the ADDF has awarded over $90 million to fund more than 500 Alzheimer’s drug discovery programs and clinical trials in 18 countries.  “Trust me on this,” says Ronald Lauder.  “You will never feel better about supporting an organization, and you will never do more to help the entire world.”  To find out how you can help, click here.
Judy Glickman and Leonard A. Lauder Paula Zahn and Bonnie Pfeifer Evans
Renee Belfer, Robert Belfer, and Barbara Tober
Kari Tiedemann Michael Cohen and Deborah Krulewitch
Meryl Comer Wendy Stapleton Reyes and Taylor McKenzie-Jackson
Jo Carole Lauder, William Lauder, and Sheila Johnson Robbins
Alex Tingle and Eric Wittenberg
Alice Shure and Phyllis Rosenthal
Marjorie Reed Gordon with George and Joan Schiele
William Lauder and Lori Tritsch
Bonnie Pfeifer Evans and Carlos Buesa
Jane Herschaft, Danielle Englebardt, and Bonnie Engelbardt Lautenberg
Mary Ann Freda and Jane Hertzmark Hudis
Joanna and Daniel Rose
Charles M. Diker and Barbara Tober